Objective: This study aimed to investigate the effects of drug holidays during summer vacations among children with attention deficit/hyperactivity disorder (ADHD) who were treated with methylphenidate in terms of ADHD symptoms and executive functions.
Methods: The study was a prospective cohort study that includes pre-treatment, post-treatment and post-drug holiday evaluations. ADHD symptom severity was evaluated with the Clinical Global Impression Scale (CGI), the Conners' Parental Rating Scale-Short Form (CPRS) and the Conners' Teacher Rating Scale- Short Form (CTRS). The Stroop Color Word Test- TBAG Form (SCWT) was used to evaluate executive functions. Fifty-one patients participated in the study according to the inclusion and exclusion criteria. Methylphenidate (MPH) was started at 0.5 mg/kg/day and titrated weekly to a maximum of 1.2 mg/kg/day. During the follow-up period, 22 (43.0%) of the patients stopped treatment.
Results: Completion times for all SCWT subtests were significantly reduced after treatment ( < 0.001, = 0.002, < 0.001, = 0.002, < 0.001; respectively). Mean number of corrections in SCWT-3 and mean number of errors as well as corrections in SCWT-5 significantly reduced after treatment ( = 0.047, = 0.005, = 0.007; respectively). Mean number of corrections in SCWT-3 and mean number of errors in SCWT-5 increased significantly after drug holiday compared to post-treatment ( = 0.032 and = 0.037; respectively).
Conclusion: Our results suggest that psychomotor speed and resistance to interference improved in children with ADHD receiving methylphenidate treatment. Drug holidays did not affect psychomotor speed while beneficial effects on resistance to interference were reduced with drug holidays.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/08039488.2020.1855242 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relative Forgiveness of Different Allopurinol Implementation Patterns in People with Gout and their Impact on Clinical Outcomes: a Simulation Study.
Clin Pharmacokinet
December 2024
Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Background And Objective: Adherence to urate-lowering therapy among people with gout is poor, so it is important to understand which day-to-day medication-taking ('implementation') patterns are most likely to lead to suboptimal serum urate concentrations and worsen clinical outcomes. This study aimed to (1) determine the relative forgiveness (RF) of allopurinol with hypothetical and real-life implementation patterns in people with gout, (2) explore the use of RF as a means of identifying suboptimal implementation patterns, (3) assess the impact of suboptimal implementation patterns on clinical outcomes.
Methods: A simulation study was conducted using a pharmacokinetic-pharmacodynamic model for allopurinol and serum urate to determine the RF of allopurinol implementation patterns.
Topical 5-fluorouracil 1% as first-line therapy for giant ocular surface squamous neoplasia.
J Fr Ophtalmol
December 2024
Cornea and Refractive Surgery Department, Asociación para Evitar la Ceguera en México, I.A.P., Mexico City, Mexico.
Purpose: To evaluate the clinical outcomes of topical 5-fluorouracil (5-FU) 1% as first-line therapy for giant ocular surface squamous neoplasia (OSSN).
Materials And Methods: This was a non-comparative cohort study. We included patients with biopsy-proven giant OSSN in a tertiary-care setting.
Recurrent Corneal Erosion Induced by 1% 5-Fluorouracil Solution.
Cureus
November 2024
Ophthalmology, Hiroshima University, Hiroshima, JPN.
Cytotoxic anticancer drug solution eye drops can hinder the cell division of corneal basal cell division and corneal limbal epithelial stem cell migration. We discuss a case involving recurrent corneal epithelial erosions induced by 1% 5-fluorouracil (5-FU) solution eye drops. A 68-year-old male with conjunctival papilloma on his left eye underwent recurrences three times and additional tumor excision.
View Article and Find Full Text PDFDrug-resistant F V600E-mutant recurrent pleomorphic xanthoastrocytoma, CNS WHO Grade 3 successfully resolved with incidental discontinuation of combined BRAF and MEK inhibitor therapy.
Surg Neurol Int
November 2024
Department of Neurosurgery, Kumamoto University Hospital, Kumamoto, Japan.
Background: Combination therapy with BRAF and MEK inhibitor holds promise for treating gliomas harboring the V600E mutation; however, the development of acquired resistance remains a challenge.
Case Description: We describe a case of repeated recurrent mutant pleomorphic xanthoastrocytoma (central nervous system World Health Organization grade 3) treated with combination therapy with BRAF and MEK inhibitor. The patient received dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor); however, she developed resistance to the combination therapy.
Drug Holidays May Attenuate Beneficial Effects of Treatment on Emotion Regulation and Recognition Among Children with ADHD: A Single-Center, Prospective Study.
Psychiatry Clin Psychopharmacol
November 2024
Department of Child and Adolescent Psychiatry, Abant İzzet Baysal University Faculty of Medicine, Bolu, Türkiye.
Article Synopsis
- This study examined how taking breaks from the ADHD medication methylphenidate (MPH) during summer vacations affects ADHD symptoms and emotion regulation (ER) in children.
- Fifty-six children participated, with evaluations happening before treatment, after treatment, and after the drug holidays. Out of those, 39 had complete data for analysis.
- Results showed that while MPH treatment significantly reduced irritability and improved emotion recognition skills, these positive effects diminished after drug holidays, indicating the medication's benefits may be temporary.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!